Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of ...

Retrieved on: 2022-04-09 23:40:36

Tags for this article:

Click the tags to see associated articles and topics

Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of .... View article details on hiswai:

Excerpt

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company ... PipelineReview.com is powered by La Merie Business Intelligence La Merie ...

Article found on: pipelinereview.com